Reshaping the future of nanopharmaceuticals: ad iudicium
- PMID: 21992178
- DOI: 10.1021/nn2038252
Reshaping the future of nanopharmaceuticals: ad iudicium
Abstract
We present views on the future development of biologics-based nanopharmaceuticals from a "high risk-high gain" perspective and within the context of personalized therapies. Integrated scientific, commercial, and societal aspects are addressed, and provocative combined realistic biotech, computational, and nanotech approaches for tailor-made engineering of nanopharmaceuticals are discussed.
© 2011 American Chemical Society
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
